<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05021731</url>
  </required_header>
  <id_info>
    <org_study_id>PI21/00444</org_study_id>
    <nct_id>NCT05021731</nct_id>
  </id_info>
  <brief_title>Short-course Rifamycin-based Regimens for Latent Tuberculosis in Patients With End-stage Kidney Disease</brief_title>
  <official_title>Comparison of 3-month Once-weekly Isoniazid Plus Rifapentine, 4-month Daily Rifampicin, and 3-month Daily Isoniazid Plus Rifampicin for the Treatment Latent Tuberculosis in Patients With End-stage Kidney Disease: A Randomised Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Miguel Santín</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut d'Investigació Biomèdica de Bellvitge</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto de Salud Carlos III</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Universitari de Bellvitge</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective To determine if treatment completion with a 4-month rifampin (4R) or 3-month&#xD;
      rifapentine (P) + isoniazid (H) weekly for 12 weeks (3HP) regimens is better than with a&#xD;
      3-month (3HR) regimen for treatment of latent tuberculosis (TB) infection (LTBI) in patients&#xD;
      with end stage kidney disease.&#xD;
&#xD;
      Methods Design: Multicenter, prospective, parallel-group, open-label, controlled clinical&#xD;
      trial.&#xD;
&#xD;
      Study population: All adult patients with ESKD in who treatment for LTBI is prescribed at 7&#xD;
      hospitals.&#xD;
&#xD;
      Interventions: Patients who accept participation, will be randomly assigned to one of the 3&#xD;
      arms: 3HR (control) (90 doses), 4R (120 doses) or 3HP (12 doses).&#xD;
&#xD;
      Outcome: Proportion of participants who discontinue permanently the assigned treatment.&#xD;
      Follow-up: Periodic assessment for permanent or temporary discontinuation, and adverse events&#xD;
      of the assigned treatment.&#xD;
&#xD;
      Sample size: 225 subjects (75 per arm) will be needed to demonstrate, if exists, a 0.16&#xD;
      decrease in permanent discontinuation rates in the experimental arms (4R and 3HP) with&#xD;
      respect to the control arm (3HR), with α= 0.025, β= 0.20, and 5% expected losses, and&#xD;
      assuming a 0.25 proportion of permanent discontinuation in the control.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2022</start_date>
  <completion_date type="Anticipated">April 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2025</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment completion</measure>
    <time_frame>From date of randomization until the date of completion of the assigned treatment, or date of lost to follow-up, or date of death, whichever came first, assessed up to 16 weeks for the 3HR arm, 14 weeks for the 3HP arm, and 20 weeks for the 4R arm.</time_frame>
    <description>Proportion of participants who complete the treatment assigned at randomization, defined as: 1) 90 doses within a maximum of 16 weeks, without interruptions longer than 2 weeks, and no more than in 2 occasions, for 3HR (control arm); 2) 12 doses within a maximum of 14 weeks, without interruptions longer than 10 days, for 3HP (experimental arm 1), and 3) 120 doses within a maximum of 20 weeks, without interruptions longer than 2 weeks, and no more than in two occasions, for 4R (experimental arm 2).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Permanent discontinuation because of adverse events</measure>
    <time_frame>From date of randomization until the date of completion of the assigned treatment, or date of lost to follow-up, or date of death, whichever came first, assessed up to 16 weeks for the 3HR arm, 14 weeks for the 3HP arm, and 20 weeks for the 4R arm.</time_frame>
    <description>Proportion of participants who permanently discontinue the treatment assigned, because of adverse events, regardless the relationship of the event/s to the study treatment.&#xD;
Permanent discontinuation defined as: 1) not completion of 90 doses within a maximum of 16 weeks, without interruptions longer than 2 weeks, and no more than in 2 occasions, for 3HR (control arm); 2) not completion 12 doses within a maximum of 14 weeks, without interruptions longer than 10 days, for 3HP (experimental arm 1), and 3) not completion of 120 doses within a maximum of 20 weeks, without interruptions longer than 2 weeks, and no more than in two occasions, for 4R (experimental arm 2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Permanent discontinuation because of adverse events related to the treatment</measure>
    <time_frame>From date of randomization until the date of completion of the assigned treatment, or date of lost to follow-up, or date of death, whichever came first, assessed up to 16 weeks for the 3HR arm, 14 weeks for the 3HP arm, and 20 weeks for the 4R arm.</time_frame>
    <description>Proportion of participants who permanently discontinue the treatment assigned, because of adverse events related to he study treatment&#xD;
Permanent discontinuation defined as: 1) not completion of 90 doses within a maximum of 16 weeks, without interruptions longer than 2 weeks, and no more than in 2 occasions, for 3HR (control arm); 2) not completion 12 doses within a maximum of 14 weeks, without interruptions longer than 10 days, for 3HP (experimental arm 1), and 3) not completion of 120 doses within a maximum of 20 weeks, without interruptions longer than 2 weeks, and no more than in two occasions, for 4R (experimental arm 2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>From date of randomization until four weeks after completing the assigned treatment, or lost to follow-up, assessed up to 17 weeks for the 3HR arm, 15 weeks for the 3HP arm, and 21 weeks for the 4R arm.</time_frame>
    <description>Number of participants who die while on the study, regardless of its relationship to the treatment assigned at randomization</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">225</enrollment>
  <condition>Latent Tuberculosis</condition>
  <condition>Kidney Failure</condition>
  <arm_group>
    <arm_group_label>3-month Isoniazid plus Rifampicin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Daily isoniazid 300 mg plus rifampicin 600 mg for three months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3-month Isoniazid plus Rifapentine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weekly isoniazid 900 mg plus rifapentine 900 mg for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4-month Rifampicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily rifampicin 600 mg for four months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampicin plus Isoniazid</intervention_name>
    <description>Administration of rifampicin plus isoniazid for latent tuberculosis</description>
    <arm_group_label>3-month Isoniazid plus Rifampicin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifapentine plus Isoniazid</intervention_name>
    <description>Administration of rifapentine plus isoniazid for latent tuberculosis</description>
    <arm_group_label>3-month Isoniazid plus Rifapentine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampicin alone</intervention_name>
    <description>Administration of rifampicin alone for latent tuberculosis</description>
    <arm_group_label>4-month Rifampicin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 years or older&#xD;
&#xD;
          2. Stage 5 kidney disease (glomerular filtrate rate &lt;15 mL/minute or under substitutive&#xD;
             renal therapy&#xD;
&#xD;
          3. Informed written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior allergy/intolerance to rifamycins or isoniazid&#xD;
&#xD;
          2. Pregnancy or breastfeeding&#xD;
&#xD;
          3. Pre-treatment transaminases (ALT and/or AST) &gt;5-fold of normality titer&#xD;
&#xD;
          4. Concomitant drugs contraindicated with rifamycins&#xD;
&#xD;
          5. Having received rifamycins or isoniazid within the two previous weeks&#xD;
&#xD;
          6. Weigh &lt;32 Kgs&#xD;
&#xD;
          7. Inability to understand the nature of the study or to give written consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 13, 2021</study_first_submitted>
  <study_first_submitted_qc>August 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2021</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitari de Bellvitge</investigator_affiliation>
    <investigator_full_name>Miguel Santín</investigator_full_name>
    <investigator_title>Senior consultant in infectious diseases</investigator_title>
  </responsible_party>
  <keyword>Tuberculosis</keyword>
  <keyword>Rifamycins</keyword>
  <keyword>Rifampicin</keyword>
  <keyword>Rifapentine</keyword>
  <keyword>Kidney failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Latent Tuberculosis</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Rifapentine</mesh_term>
    <mesh_term>Isoniazid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

